Ceribell Reports Strong 36% Revenue Growth, Expands Product Pipeline with Delirium Clearance & Stroke Designation

summarizeSummary

Ceribell reported strong 36% revenue growth for 2025, driven by increased adoption of its EEG system, and expanded its product pipeline with FDA clearances for delirium monitoring and Breakthrough Device Designation for LVO stroke detection.

check_boxKey Events

• Strong Revenue Growth and High Margins

  Ceribell reported total revenue of $89.1 million for 2025, a 36% increase from $65.4 million in 2024. Gross margin remained high at 88% for 2025, up from 87% in 2024, indicating efficient operations.

• Significant Product Pipeline Expansion

  The company received FDA 510(k) clearance for its proprietary delirium monitoring solution in December 2025, making it the first and only FDA-cleared device for this indication. Additionally, in January 2026, it received FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution, further expanding its addressable market beyond seizures.

• Solid Liquidity and Cash Runway

  As of December 31, 2025, Ceribell had $159.3 million in cash and cash equivalents and marketable securities, which management believes is sufficient to fund operations for at least the next 12 months.

• Ongoing Patent Infringement Litigation

  In July 2025, Ceribell filed patent infringement complaints against Natus Medical Incorporated, alleging infringement on six patents related to its EEG headband and electrode designs. The U.S. District Court for the District of Delaware has stayed the action pending the USITC investigation.

auto_awesomeAnalysis

Ceribell's annual report highlights robust financial performance with significant revenue growth and high gross margins, underscoring strong market adoption of its EEG system. The company's strategic expansion into new indications, particularly the FDA clearance for delirium monitoring and Breakthrough Device Designation for LVO stroke detection, are pivotal for future growth and significantly broaden its addressable market. While the company continues to incur net losses, this is typical for a high-growth medical technology firm investing heavily in R&D and commercialization. The solid cash position provides a healthy runway for these initiatives. Investors should monitor the progress of these new indications and the outcome of the patent litigation, as they are key to Ceribell's long-term value proposition.